Startup profile · funding coverage
Aureka Biotechnologies funding, valuation and investors
AI-native TechBio building biological foundation models with closed-loop wet-lab infrastructure.
Verified company research · funding, investors and latest developments
Keep track of Aureka Biotechnologies
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$100M · August 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$100M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Laguna Hills, California / Shanghai, China
Investors in latest funding
Lead: Granite Asia , Strategic investor (undisclosed)
Other: HighLight Capital , MPCi , NRL Capital
Overview
Aureka Biotechnologies is an AI-native TechBio company with bases in Laguna Hills, California and Shanghai. It develops biological foundation models (AuraIDE; open-source OpenDDE) and Lab-in-the-Loop infrastructure that couples molecular generation with high-throughput experimental validation for antibody discovery. Founded in 2023 by Dr. Weian Zhao.
In August 2026 Aureka raised a $100 million Series B with Granite Asia funding the first tranche exclusively, a strategic investor leading a subsequent tranche, and participation from HighLight Capital, MPCi, and NRL Capital — nearly $200 million raised to date. The company cites strategic pharma partnerships and tens of millions in revenue over two years.
Why Aureka Biotechnologies is interesting
$100M Series B (Aug 2026, ~$200M cumulative) to scale AuraIDE — models that improve from proprietary Lab-in-the-Loop experiments, not only public protein datasets.
Product & use cases
Closed-loop AI-for-science stack: biological foundation models plus single-cell functional screening and automated experiments that feed continuous model post-training for antibody design.
- De novo antibody and biomolecular design with wet-lab feedback
- Partner with pharma on hard targets (e.g., GPCRs, dual-target antibodies)
- Benchmark and extend open biomolecular models via OpenDDE
Key facts
- Series B (Aug 2026): $100M; ~$200M cumulative (PR Newswire)
- First tranche: Granite Asia (exclusive); later tranche led by undisclosed strategic; HLC, MPCi, NRL follow-on
- Products: AuraIDE foundation model; OpenDDE open-source; Lab-in-the-Loop platforms
- Tens of millions revenue over ~2 years from discovery partnerships (company)
- No VCT /fund/ IDs yet for Granite Asia / HLC / MPCi / NRL — names press-sourced
Funding history (newest first)
Series B
2026-08 $100M- Granite Asia (lead)
- Strategic investor (undisclosed) (lead)
- HighLight Capital (participant)
- MPCi (participant)
- NRL Capital (participant)
Source: Read source · prnewswire.com
Related reading
Explore the analysis behind recent funding rounds and company developments.
Competitive landscape
Edge: Owns the experimental flywheel that generates proprietary functional data for foundation-model training — not only static public corpora.
Buyers increasingly want closed-loop platforms that produce developable assets, not structure scores alone. Aureka’s underwriting questions are partner concentration, geography/IP, and how fast Lab-in-the-Loop data improves real programs.
-
Chai Discovery adjacent
Structure/design-focused TechBio peer in the foundation-model wave.
-
Classic CRO + ML bolt-ons adjacent
Experiment capacity without owned biological foundation models.
-
Pharma internal AI groups adjacent
Build-vs-buy partners and competitors depending on program.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Aureka Biotechnologies
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.